{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T03:23:47Z","timestamp":1793503427701,"version":"4.5.0"},"reference-count":240,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ejca.2026.116764","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T23:08:12Z","timestamp":1778108892000},"page":"116764","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment - update 2026"],"prefix":"10.1016","volume":"243","author":[{"given":"Alexander J.","family":"Stratigos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clio","family":"Dessinioti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Garbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celeste","family":"Lebbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Amaral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronique","family":"Bataille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Dreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"Dummer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Concetta","family":"Fargnoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Maria","family":"Forsea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoffer","family":"Gebhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine A.","family":"Harwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Hauschild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Hoeller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidija","family":"Kandolf-Sekulovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Kaufmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole WJ","family":"Kelleners-Smeets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Koelblinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimilios","family":"Lallas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Leiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Liopyris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronique","family":"del Marmol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Moreno-Ramirez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Pellacani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ketty","family":"Peris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Saiag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Tagliaferri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myrto","family":"Trakatelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Vieira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Zalaudek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petr","family":"Arenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander C.J.","family":"van Akkooi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander M.M.","family":"Eggermont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Lorigan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Mandala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep","family":"Malvehy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2026.116764_bib1","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/bjd.19621","article-title":"British Association of Dermatologists guidelines for the management of people with cutaneous squamous cell carcinoma 2020","volume":"184","author":"Keohane","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2026.116764_bib2","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1159\/000524460","article-title":"A Sensitivity Meta-Analysis of Disease-Specific Death in Localized Cutaneous Squamous Cell Carcinoma","volume":"238","author":"Dessinioti","year":"2022","journal-title":"Dermatology"},{"key":"10.1016\/j.ejca.2026.116764_bib3","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1111\/jdv.16268","article-title":"Treatment of keratinocyte carcinoma in elderly patients - a review of the current literature","volume":"34","author":"Leus","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ejca.2026.116764_bib4","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.ejca.2021.08.018","article-title":"Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma","volume":"157","author":"Baggi","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2026.116764_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.686308","article-title":"Cemiplimab in an Elderly Frail Population of Patients With Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Center Real-Life Experience From Italy","volume":"11","author":"Strippoli","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejca.2026.116764_bib6","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.1007\/s00432-022-04246-0","article-title":"Anti-PD-1 for the treatment of advanced cutaneous squamous cell carcinoma in elderly patients: a French multicenter retrospective survey","volume":"149","author":"Samaran","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116764_bib7","first-page":"999","article-title":"Local surgical treatment of cutaneous squamous cell carcinoma: deficits and controversies in the literature","volume":"17","author":"Breuninger","year":"2019","journal-title":"J der Dtsch Dermatol Ges = J Ger Soc Dermatol JDDG"},{"key":"10.1016\/j.ejca.2026.116764_bib8","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1111\/bjd.17510","article-title":"The illusion of conventional histological resection margin control","volume":"180","author":"van Delft","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2026.116764_bib9","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.jaad.2017.10.007","article-title":"Guidelines of care for the management of cutaneous squamous cell carcinoma","volume":"78","author":"Alam","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2026.116764_bib10","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1007\/s12094-024-03826-5","article-title":"Recommendations for the management of cutaneous squamous cell carcinoma: a systematic multidisciplinary Delphi consensus approach","volume":"27","author":"Munoz Couselo","year":"2025","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.ejca.2026.116764_bib11","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1080\/09546634.2018.1441493","article-title":"Risk factors for positive margins after wide local excision of cutaneous squamous cell carcinoma","volume":"29","author":"Stewart","year":"2018","journal-title":"J Dermatol Treat"},{"key":"10.1016\/j.ejca.2026.116764_bib12","volume":"Version 1","author":"Bordeaux","year":"2026","journal-title":"National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines Oncology. Squamous cell skin cancer"},{"key":"10.1016\/j.ejca.2026.116764_bib13","first-page":"400","article-title":"S3 guideline for actinic keratosis and cutaneous squamous cell carcinoma (cSCC) - short version, part 2: epidemiology, surgical and systemic treatment of cSCC, follow-up, prevention and occupational disease","volume":"18","author":"Leiter","year":"2020","journal-title":"J der Dtsch Dermatol Ges = J Ger Soc Dermatol JDDG"},{"key":"10.1016\/j.ejca.2026.116764_bib14","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/PAP.0000000000000157","article-title":"Cutaneous Squamous Cell Carcinoma: Review of the Eighth Edition of the American Joint Committee on Cancer Staging Guidelines, Prognostic Factors, and Histopathologic Variants","volume":"24","author":"Motaparthi","year":"2017","journal-title":"Adv Anat Pathol"},{"key":"10.1016\/j.ejca.2026.116764_bib15","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/0190-9622(92)70178-I","article-title":"Surgical margins for excision of primary cutaneous squamous cell carcinoma","volume":"27","author":"Brodland","year":"1992","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2026.116764_bib16","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/01.PRS.0000067479.77859.31","article-title":"Excision margins for nonmelanotic skin cancer","volume":"112","author":"Thomas","year":"2003","journal-title":"Plast Reconstr Surg"},{"key":"10.1016\/j.ejca.2026.116764_bib17","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1159\/000444051","article-title":"Squamocellular Carcinoma of the Skin: Clinicopathological Features Predicting the Involvement of the Surgical Margins and Review of the Literature","volume":"232","author":"Ribero","year":"2016","journal-title":"Dermatology"},{"issue":"5","key":"10.1016\/j.ejca.2026.116764_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1468-3083.2011.04296.x","article-title":"Guidelines for the diagnosis and treatment of cutaneous squamous cell carcinoma and precursor lesions","volume":"25","author":"Bonerandi","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ejca.2026.116764_bib19","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1177\/1203475415582318","article-title":"Non-melanoma Skin Cancer in Canada Chapter 5: Management of Squamous Cell Carcinoma","volume":"19","author":"Sapijaszko","year":"2015","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.ejca.2026.116764_bib20","doi-asserted-by":"crossref","first-page":"e288","DOI":"10.1111\/1346-8138.15889","article-title":"Japanese Dermatological Association Guidelines: Outlines of Guidelines for Cutaneous Squamous Cell Carcinoma 2020","volume":"48","author":"Ansai","year":"2021","journal-title":"J Dermatol"},{"key":"10.1016\/j.ejca.2026.116764_bib21","doi-asserted-by":"crossref","DOI":"10.1097\/DSS.0000000000003606","article-title":"Rate and Characteristics of Incompletely Excised Cutaneous Squamous Cell Carcinoma: A Dermatological Daily Practice Multicenter Prospective Cohort Study","author":"van Lee","year":"2022","journal-title":"Dermatol Surg"},{"issue":"1","key":"10.1016\/j.ejca.2026.116764_bib22","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/jdv.17531","article-title":"Overview of guideline recommendations for the management of high-risk and advanced cutaneous squamous cell carcinoma","volume":"36","author":"Dessinioti","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ejca.2026.116764_bib23","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0007-1226(03)00028-6","article-title":"Multiprofessional guidelines for the management of the patient with primary cutaneous squamous cell carcinoma","volume":"56","author":"Motley","year":"2003","journal-title":"Br J Plast Surg"},{"key":"10.1016\/j.ejca.2026.116764_bib24","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.bjps.2012.12.016","article-title":"Guidelines for the excision of cutaneous squamous cell cancers in the United Kingdom: the best cut is the deepest","volume":"66","author":"Khan","year":"2013","journal-title":"J Plast Reconstr Aesthet Surg"},{"key":"10.1016\/j.ejca.2026.116764_bib25","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.1017\/S0022215116000554","article-title":"Non-melanoma skin cancer: United Kingdom National Multidisciplinary Guidelines","volume":"130","author":"Newlands","year":"2016","journal-title":"J Laryngol Otol"},{"key":"10.1016\/j.ejca.2026.116764_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103005","article-title":"Guidelines for the diagnosis and treatment of cutaneous squamous cell carcinoma: a GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology","volume":"9","author":"Queirolo","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejca.2026.116764_bib27","article-title":"European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment-Update 2023","volume":"193","author":"Stratigos","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2026.116764_bib28","first-page":"1088","article-title":"Narrower clinical margin in high or very high-risk squamous cell carcinoma: a retrospective, multicenter study of 1,000 patients","volume":"20","author":"Baba","year":"2022","journal-title":"J der Dtsch Dermatol Ges = J Ger Soc Dermatol JDDG"},{"key":"10.1016\/j.ejca.2026.116764_bib29","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1111\/jdv.20250","article-title":"Histological deep margins in cutaneous squamous cell carcinoma of the scalp and risk of recurrence","volume":"39","author":"Verdaguer-Faja","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ejca.2026.116764_bib30","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/2000656X.2022.2060993","article-title":"Galea vs periosteum: impact of excision depth on outcomes for cutaneous squamous cell carcinoma of the scalp","volume":"57","author":"Brewer","year":"2023","journal-title":"J Plast Surg Hand Surg"},{"key":"10.1016\/j.ejca.2026.116764_bib31","article-title":"Management of close\/positive margins in cutaneous squamous cell carcinoma of the head and neck: a systematised review","volume":"7","author":"Martin","year":"2024","journal-title":"Head Neck"},{"key":"10.1016\/j.ejca.2026.116764_bib32","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/bjd.17188","article-title":"Recurrence rates of cutaneous squamous cell carcinoma of the head and neck after Mohs micrographic surgery vs. standard excision: a retrospective cohort study","volume":"181","author":"van Lee","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2026.116764_bib33","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/0190-9622(92)70144-5","article-title":"Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality selection","volume":"26","author":"Rowe","year":"1992","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2026.116764_bib34","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1001\/jamadermatol.2023.1353","article-title":"Validation of the 2022 National Comprehensive Cancer Network Risk Stratification for Cutaneous Squamous Cell Carcinoma","volume":"159","author":"Stevens","year":"2023","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ejca.2026.116764_bib35","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jaad.2025.04.010","article-title":"A multicenter validation study of Mohs micrographic surgery versus wide local excision in primary high-stage cutaneous squamous cell carcinoma","volume":"93","author":"Wang","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2026.116764_bib36","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1111\/ced.15187","article-title":"A review of Mohs micrographic surgery for skin cancer. Part 3: Squamous cell carcinoma","volume":"47","author":"Hunt","year":"2022","journal-title":"Clin Exp Dermatol"},{"issue":"5","key":"10.1016\/j.ejca.2026.116764_bib37","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/j.1468-3083.2007.02187.x","article-title":"A confusing world: what to call histology of three-dimensional tumour margins?","volume":"21","author":"Moehrle","year":"2007","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ejca.2026.116764_bib38","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1111\/ddg.12665","article-title":"S1 guideline: microscopically controlled surgery (MCS)","volume":"13","author":"Loser","year":"2015","journal-title":"J der Dtsch Dermatol Ges = J Ger Soc Dermatol JDDG"},{"key":"10.1016\/j.ejca.2026.116764_bib39","first-page":"1080","article-title":"The Muffin technique--an alternative to Mohs' micrographic surgery","volume":"4","author":"Mohrle","year":"2006","journal-title":"J der Dtsch Dermatol Ges = J Ger Soc Dermatol JDDG"},{"issue":"2","key":"10.1016\/j.ejca.2026.116764_bib40","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jaad.2015.04.027","article-title":"Ex vivo fluorescence confocal microscopy in conjunction with Mohs micrographic surgery for cutaneous squamous cell carcinoma","volume":"73","author":"Longo","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2026.116764_bib41","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jaad.2005.02.059","article-title":"Cutaneous squamous cell carcinoma treated with Mohs micrographic surgery in Australia I. Experience over 10 years","volume":"53","author":"Leibovitch","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2026.116764_bib42","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1111\/j.1524-4725.2010.01576.x","article-title":"Mohs surgery is effective for high-risk cutaneous squamous cell carcinoma","volume":"36","author":"Pugliano-Mauro","year":"2010","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.ejca.2026.116764_bib43","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1038\/jid.2012.403","article-title":"Tumor recurrence 5 years after treatment of cutaneous basal cell carcinoma and squamous cell carcinoma","volume":"133","author":"Chren","year":"2013","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.ejca.2026.116764_bib44","doi-asserted-by":"crossref","first-page":"f6153","DOI":"10.1136\/bmj.f6153","article-title":"Interventions for non-metastatic squamous cell carcinoma of the skin: systematic review and pooled analysis of observational studies","volume":"347","author":"Lansbury","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.ejca.2026.116764_bib45","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.jaad.2018.09.015","article-title":"Clinical outcomes in high-risk squamous cell carcinoma patients treated with Mohs micrographic surgery alone","volume":"80","author":"Marrazzo","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2026.116764_bib46","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jaad.2019.06.1303","article-title":"Long-term clinical outcomes of patients with invasive cutaneous squamous cell carcinoma treated with Mohs micrographic surgery: A 5-year, multicenter, prospective cohort study","volume":"82","author":"Tschetter","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2026.116764_bib47","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.jaad.2019.12.049","article-title":"Outcomes in intermediate-risk squamous cell carcinomas treated with Mohs micrographic surgery compared with wide local excision","volume":"82","author":"Xiong","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2026.116764_bib48","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jaad.2022.06.1169","article-title":"Clinical outcomes of high-risk cutaneous squamous cell carcinomas treated with Mohs surgery alone: An analysis of local recurrence, regional nodal metastases, progression-free survival, and disease-specific death","volume":"88","author":"Soleymani","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2026.116764_bib49","doi-asserted-by":"crossref","first-page":"5124","DOI":"10.1245\/s10434-022-11669-z","article-title":"Benchmarking Survival Outcomes Following Surgical Management of pT3 and pT4 Cutaneous Squamous Cell Carcinoma of the Head and Neck","volume":"29","author":"Yung","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejca.2026.116764_bib50","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1097\/DSS.0000000000003462","article-title":"Complete Margin Assessment Versus Sectional Assessment in Surgically Excised High-Risk Keratinocyte Carcinomas: A Systematic Review and Meta-Analysis","volume":"48","author":"Fraga","year":"2022","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.ejca.2026.116764_bib51","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.jaad.2021.07.059","article-title":"Cost effectiveness of intermediate-risk squamous cell carcinoma treated with Mohs micrographic surgery compared with wide local excision","volume":"86","author":"Udkoff","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2026.116764_bib52","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/j.1524-4725.2009.01095.x","article-title":"Surgical monotherapy versus surgery plus adjuvant radiotherapy in high-risk cutaneous squamous cell carcinoma: a systematic review of outcomes","volume":"35","author":"Jambusaria-Pahlajani","year":"2009","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.ejca.2026.116764_bib53","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1097\/01.MLG.0000158349.64337.ED","article-title":"Surgery and adjuvant radiotherapy in patients with cutaneous head and neck squamous cell carcinoma metastatic to lymph nodes: combined treatment should be considered best practice","volume":"115","author":"Veness","year":"2005","journal-title":"Laryngoscope"},{"key":"10.1016\/j.ejca.2026.116764_bib54","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1001\/jamaoto.2018.4515","article-title":"Outcomes of Cutaneous Squamous Cell Carcinoma in the Head and Neck Region With Regional Lymph Node Metastasis: A Systematic Review and Meta-analysis","volume":"145","author":"Sahovaler","year":"2019","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.ejca.2026.116764_bib55","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/hed.20048","article-title":"Cutaneous metastatic squamous cell carcinoma to the parotid gland: analysis and outcome","volume":"26","author":"Audet","year":"2004","journal-title":"Head Neck"},{"key":"10.1016\/j.ejca.2026.116764_bib56","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/hed.27912","article-title":"Predictors of distant metastatic recurrence in head and neck cutaneous squamous cell carcinoma with lymph node metastases treated with curative intent: A multicenter study","volume":"47","author":"Ebrahimi","year":"2025","journal-title":"Head Neck"},{"key":"10.1016\/j.ejca.2026.116764_bib57","doi-asserted-by":"crossref","first-page":"5017","DOI":"10.1245\/s10434-023-13306-9","article-title":"Oncological Outcome After Lymph Node Dissection for Cutaneous Squamous Cell Carcinoma","volume":"30","author":"Huis In 't Veld","year":"2023","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejca.2026.116764_bib58","doi-asserted-by":"crossref","DOI":"10.1245\/s10434-025-18035-9","article-title":"Response-Adapted Oncologic Surgery in Cutaneous Squamous Cell Carcinoma: A Paradigm Shift Following Neoadjuvant Immunotherapy","author":"Yaniv","year":"2025","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejca.2026.116764_bib59","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1200\/JCO-25-00387","article-title":"Response-Adapted Surgical and Radiotherapy De-Escalation in Resectable Cutaneous Squamous Cell Cancer Using Pembrolizumab: The De-Squamate Study","volume":"43","author":"Ladwa","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116764_bib60","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.bjoms.2014.01.015","article-title":"Management of regional metastatic disease in head and neck cutaneous malignancy. 1. Cutaneous squamous cell carcinoma","volume":"52","author":"Gurney","year":"2014","journal-title":"Br J Oral Maxillofac Surg"},{"key":"10.1016\/j.ejca.2026.116764_bib61","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/MOO.0b013e328343e811","article-title":"Management of the neck in metastatic cutaneous squamous cell carcinoma of the head and neck","volume":"19","author":"D'Souza","year":"2011","journal-title":"Curr Opin Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.ejca.2026.116764_bib62","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/hed.10063","article-title":"Significance of clinical stage, extent of surgery, and pathologic findings in metastatic cutaneous squamous carcinoma of the parotid gland","volume":"24","author":"O'Brien","year":"2002","journal-title":"Head Neck"},{"key":"10.1016\/j.ejca.2026.116764_bib63","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1002\/hed.20417","article-title":"Patterns of lymph node spread of cutaneous squamous cell carcinoma of the head and neck","volume":"28","author":"Vauterin","year":"2006","journal-title":"Head Neck"},{"key":"10.1016\/j.ejca.2026.116764_bib64","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1002\/hed.21574","article-title":"Outcome of patients treated surgically for lymph node metastases from cutaneous squamous cell carcinoma of the head and neck","volume":"33","author":"Givi","year":"2011","journal-title":"Head Neck"},{"key":"10.1016\/j.ejca.2026.116764_bib65","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1002\/hed.21332","article-title":"Predicting the pattern of regional metastases from cutaneous squamous cell carcinoma of the head and neck based on location of the primary","volume":"32","author":"Ebrahimi","year":"2010","journal-title":"Head Neck"},{"key":"10.1016\/j.ejca.2026.116764_bib66","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1053\/ejso.2002.1330","article-title":"Treatment results of regional metastasis from cutaneous head and neck squamous cell carcinoma","volume":"29","author":"Jol","year":"2003","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2026.116764_bib67","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1017\/S0022215112002101","article-title":"patients with metastatic cutaneous head and neck squamous cell carcinoma to cervical lymph nodes, the extent of neck dissection does not influence outcome","volume":"127","author":"Wang","year":"2013","journal-title":"J Laryngol Otol"},{"key":"10.1016\/j.ejca.2026.116764_bib68","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1002\/hed.23843","article-title":"Outcomes of nodal metastatic cutaneous squamous cell carcinoma of the head and neck treated in a regional center","volume":"37","author":"Schmidt","year":"2015","journal-title":"Head Neck"},{"key":"10.1016\/j.ejca.2026.116764_bib69","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.jaad.2017.10.007","article-title":"Guidelines of care for the management of cutaneous squamous cell carcinoma","volume":"78","author":"Work","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2026.116764_bib70","first-page":"404","article-title":"Modern head and neck brachytherapy: from radium towards intensity modulated interventional brachytherapy","volume":"6","author":"Kovacs","year":"2015","journal-title":"J Conte Brachytherapy"},{"key":"10.1016\/j.ejca.2026.116764_bib71","doi-asserted-by":"crossref","first-page":"6283","DOI":"10.1007\/s00432-023-04597-2","article-title":"Analysis of image-guided superficial radiation therapy (IGSRT) on the treatment of early-stage non-melanoma skin cancer (NMSC) in the outpatient dermatology setting","volume":"149","author":"Tran","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116764_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2026.111372","article-title":"The prospective phase I \"Flash-Skin I\" trial: ultra-high dose rate radiotherapy implementation and quality assurance at a clinical linear accelerator","volume":"216","author":"Dal Bello","year":"2026","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"key":"10.1016\/j.ejca.2026.116764_bib73","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/pro6.70010","article-title":"A safety study of ultra-high dose rate FLASH radiotherapy in the treatment of superficial skin tumors: study protocol of a phase I trial (ChiCTR2400080935)","volume":"9","author":"Yang","year":"2025","journal-title":"Precis Radiat Oncol"},{"key":"10.1016\/j.ejca.2026.116764_bib74","article-title":"Randomized phase II selection trial of FLASH and conventional radiotherapy for patients with localized cutaneous squamous cell carcinoma or basal cell carcinoma: A study protocol","volume":"45","author":"Kinj","year":"2024","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.ejca.2026.116764_bib75","doi-asserted-by":"crossref","first-page":"13","DOI":"10.14639\/0392-100X-N2786","article-title":"Management of nasal vestibule carcinomas: recommendations by the Oncological Committee of the Italian Society of Otorhinolaryngology - Head and Neck Surgery","volume":"44","author":"Bussu","year":"2024","journal-title":"Acta Otorhinolaryngol Ital"},{"key":"10.1016\/j.ejca.2026.116764_bib76","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/1754-9485.12718","article-title":"Efficacy of hypofractionated radiotherapy in patients with non-melanoma skin cancer: Results of a systematic review","volume":"62","author":"Gunaratne","year":"2018","journal-title":"J Med Imaging Radiat Oncol"},{"key":"10.1016\/j.ejca.2026.116764_bib77","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.fsc.2018.08.005","article-title":"Radiotherapy for Skin Cancers of the Face, Head, and Neck","volume":"27","author":"Mierzwa","year":"2019","journal-title":"Facial Plast Surg Clin North Am"},{"key":"10.1016\/j.ejca.2026.116764_bib78","doi-asserted-by":"crossref","DOI":"10.1111\/ajd.13025","article-title":"The role of radiotherapy in the management of non-melanoma skin cancer","author":"Garbutcheon-Singh","year":"2019","journal-title":"Austral J Dermatol"},{"key":"10.1016\/j.ejca.2026.116764_bib79","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.ijrobp.2020.03.024","article-title":"Head and Neck Cancer International Group (HNCIG) Consensus Guidelines for the Delivery of Postoperative Radiation Therapy in Complex Cutaneous Squamous Cell Carcinoma of the Head and Neck (cSCCHN)","volume":"107","author":"Porceddu","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ejca.2026.116764_bib80","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1684\/ejd.2013.2106","article-title":"Post radiation skin tumors: basal cell carcinomas, squamous cell carcinomas and angiosarcomas. A review of this late effect of radiotherapy","volume":"23","author":"Cuperus","year":"2013","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.ejca.2026.116764_bib81","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1111\/bjd.15728","article-title":"Outcomes of radiation therapy for advanced T3\/T4 nonmelanoma cutaneous squamous cell and basal cell carcinoma","volume":"178","author":"Kim","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2026.116764_bib82","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1111\/coa.12707","article-title":"Local control of 151 head and neck cutaneous squamous cell carcinoma after radiotherapy: a retrospective study on efficacy and prognostic factors","volume":"42","author":"Terra","year":"2017","journal-title":"Clin Otolaryngol"},{"key":"10.1016\/j.ejca.2026.116764_bib83","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1001\/jamaoto.2018.3650","article-title":"Association of Adjuvant Radiation Therapy With Survival in Patients With Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck","volume":"145","author":"Harris","year":"2019","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.ejca.2026.116764_bib84","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.ijrobp.2005.03.027","article-title":"Interstitial brachytherapy of periorificial skin carcinomas of the face: a retrospective study of 97 cases","volume":"63","author":"Rio","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ejca.2026.116764_bib85","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1111\/jdv.16001","article-title":"Postoperative radiotherapy provides better local control and long-term outcome in selective cases of cutaneous squamous cell carcinoma with perineural invasion","volume":"34","author":"Canueto","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ejca.2026.116764_bib86","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.jaad.2021.11.059","article-title":"Adjuvant radiotherapy may not significantly change outcomes in high-risk cutaneous squamous cell carcinomas with clear surgical margins: A systematic review and meta-analysis","volume":"86","author":"Kim","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2026.116764_bib87","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.jaad.2021.01.063","article-title":"Factors predicting outcomes of patients with high-risk squamous cell carcinoma treated with Mohs micrographic surgery","volume":"85","author":"Matsumoto","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2026.116764_bib88","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.jaad.2019.07.048","article-title":"Evaluation of the utility of localized adjuvant radiation for node-negative primary cutaneous squamous cell carcinoma with clear histologic margins","volume":"82","author":"Ruiz","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2026.116764_bib89","doi-asserted-by":"crossref","first-page":"e333","DOI":"10.1111\/jdv.20325","article-title":"Assessing outcomes of cutaneous squamous cell carcinoma with large-calibre nerve invasion as solitary high-risk factor: A single-institution cohort study","volume":"39","author":"Loranger","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ejca.2026.116764_bib90","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1111\/jdv.17330","article-title":"Efficacy and prognostic factors of adjuvant radiotherapy for cutaneous squamous cell carcinoma: A systematic review and meta-analysis","volume":"35","author":"Zhang","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ejca.2026.116764_bib91","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jaad.2022.03.044","article-title":"Adjuvant radiation following clear margin resection of high T-stage cutaneous squamous cell carcinoma halves the risk of local and locoregional recurrence: A dual-center retrospective study","volume":"87","author":"Ruiz","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2026.116764_bib92","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1093\/bjd\/ljad495","article-title":"Indications for adjuvant radiotherapy in high-risk cutaneous squamous cell carcinoma with clear margins: a Delphi consensus","volume":"190","author":"Moscarella","year":"2024","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2026.116764_bib93","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.prro.2019.10.014","article-title":"Definitive and Postoperative Radiation Therapy for Basal and Squamous Cell Cancers of the Skin: Executive Summary of an American Society for Radiation Oncology Clinical Practice Guideline","volume":"10","author":"Likhacheva","year":"2020","journal-title":"Pr Radiat Oncol"},{"key":"10.1016\/j.ejca.2026.116764_bib94","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1200\/JCO.2017.77.0941","article-title":"Postoperative Concurrent Chemoradiotherapy Versus Postoperative Radiotherapy in High-Risk Cutaneous Squamous Cell Carcinoma of the Head and Neck: The Randomized Phase III TROG 05.01 Trial","volume":"36","author":"Porceddu","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116764_bib95","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1002\/hed.21965","article-title":"Predictors of outcome in patients with metastatic cutaneous head and neck squamous cell carcinoma involving cervical lymph nodes: Improved survival with the addition of adjuvant radiotherapy","volume":"34","author":"Wang","year":"2012","journal-title":"Head Neck"},{"key":"10.1016\/j.ejca.2026.116764_bib96","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1111\/jdv.18036","article-title":"Outcome of cutaneous squamous cell carcinoma with microscopic residual disease after surgery and usefulness of postoperative radiotherapy: a retrospective cohort study","volume":"36","author":"Revelles-Penas","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ejca.2026.116764_bib97","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1805131","article-title":"PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma","volume":"379","author":"Migden","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.116764_bib98","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000775","article-title":"Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing","volume":"8","author":"Rischin","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2026.116764_bib99","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002757","article-title":"Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis","volume":"9","author":"Rischin","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2026.116764_bib100","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S1470-2045(19)30728-4","article-title":"Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial","volume":"21","author":"Migden","year":"2020","journal-title":"Lancet Oncol"},{"issue":"ement 7","key":"10.1016\/j.ejca.2026.116764_bib101","doi-asserted-by":"crossref","first-page":"S918","DOI":"10.1016\/j.annonc.2022.07.940","article-title":"Phase II study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): Final analysis from EMPOWER-CSCC-1 groups 1, 2 and 3","volume":"33","author":"Migden","year":"2022","journal-title":"Abstr 814P Ann Oncol J Eur Soc Med Oncol"},{"key":"10.1016\/j.ejca.2026.116764_bib102","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jaad.2024.06.108","article-title":"A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6","volume":"92","author":"Hughes","year":"2025","journal-title":"J Am Acad Dermatol"},{"issue":"25","key":"10.1016\/j.ejca.2026.116764_bib103","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1200\/JCO.19.03054","article-title":"Pembrolizumab Monotherapy for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Arm Phase II Trial (KEYNOTE-629)","volume":"38","author":"Grob","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116764_bib104","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.annonc.2021.07.008","article-title":"Pembrolizumab for locally advanced and recurrent\/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial","volume":"32","author":"Hughes","year":"2021","journal-title":"Ann Oncol J Eur Soc Med Oncol"},{"key":"10.1016\/j.ejca.2026.116764_bib105","first-page":"9554","article-title":"Meeting Abstract. Pembrolizumab (pembro) for locally advanced (LA) or recurrent\/metastatic (R\/M) cutaneous squamous cell carcinoma (cSCC): Long-term results of the phase 2 KEYNOTE-629 study. Poster presented at 2024 ASCO Annual Meeting","volume":"42","author":"Couselo","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116764_bib106","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007637","article-title":"Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma","volume":"11","author":"Clingan","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2026.116764_bib107","article-title":"Efficacy and safety of cosibelimab in advanced cutaneous squamous cell carcinoma: Results from a Pivotal Open-label Study with a median follow-up of >\/=2 years","author":"Ruiz","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2026.116764_bib108","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1111\/jdv.19218","article-title":"Nivolumab for locally advanced and metastatic cutaneous squamous cell carcinoma (NIVOSQUACS study)-Phase II data covering impact of concomitant haematological malignancies","volume":"37","author":"Lang","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ejca.2026.116764_bib109","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1097\/COC.0000000000000088","article-title":"Systemic Therapy in Advanced Cutaneous Squamous Cell Carcinoma (CSCC): The Roswell Park Experience and a Review of the Literature","volume":"39","author":"Jarkowski","year":"2016","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116764_bib110","doi-asserted-by":"crossref","first-page":"611","DOI":"10.2217\/fon-2020-0823","article-title":"Comparative efficacy of cemiplimab versus other systemic treatments for advanced cutaneous squamous cell carcinoma","volume":"17","author":"Keeping","year":"2021","journal-title":"Future Oncol (Lond Engl)"},{"key":"10.1016\/j.ejca.2026.116764_bib111","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ejca.2022.03.035","article-title":"Comparative efficacy analysis identifies immune checkpoint blockade as a new survival benchmark in advanced cutaneous squamous cell carcinoma","volume":"170","author":"Petzold","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2026.116764_bib112","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1200\/JCO.19.03357","article-title":"Phase II Study of Pembrolizumab As First-Line, Single-Drug Therapy for Patients With Unresectable Cutaneous Squamous Cell Carcinomas","volume":"38","author":"Maubec","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116764_bib113","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1007\/s13555-021-00598-6","article-title":"Health-Related Quality of Life of Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma Treated with Pembrolizumab in KEYNOTE-629","volume":"11","author":"Hughes","year":"2021","journal-title":"Dermatol Ther (Heide)"},{"key":"10.1016\/j.ejca.2026.116764_bib114","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s11864-025-01335-3","article-title":"The Role of Cetuximab in Non-Melanoma Skin Cancer: A Review of Clinical Evidence and Emerging Strategies","volume":"26","author":"Nuzzolese","year":"2025","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.ejca.2026.116764_bib115","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1200\/JCO.2010.34.1735","article-title":"Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin","volume":"29","author":"Maubec","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116764_bib116","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/DSS.0000000000000799","article-title":"Cisplatin and Cetuximab Treatment for Metastatic Cutaneous Squamous Cell Carcinoma: A Systematic Review","volume":"43","author":"Trodello","year":"2017","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.ejca.2026.116764_bib117","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1159\/000362384","article-title":"Cetuximab in metastatic squamous cell cancer of the skin: a Swiss case series","volume":"229","author":"Conen","year":"2014","journal-title":"Dermatology"},{"key":"10.1016\/j.ejca.2026.116764_bib118","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1159\/000461578","article-title":"Efficacy and Tolerance of Cetuximab Alone or Combined with Chemotherapy in Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma: An Open Study of 14 Patients","volume":"232","author":"Dereure","year":"2016","journal-title":"Dermatology"},{"key":"10.1016\/j.ejca.2026.116764_bib119","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.clon.2011.07.007","article-title":"Efficacy of cetuximab for unresectable or advanced cutaneous squamous cell carcinoma--a report of eight cases","volume":"23","author":"Giacchero","year":"2011","journal-title":"Clin Oncol (R Coll Radio)"},{"key":"10.1016\/j.ejca.2026.116764_bib120","article-title":"Locally advanced and unresectable cutaneous squamous cell carcinoma: outcomes of concurrent cetuximab and radiotherapy","volume":"2014","author":"Samstein","year":"2014","journal-title":"J Ski Cancer"},{"key":"10.1016\/j.ejca.2026.116764_bib121","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/DSS.0000000000001755","article-title":"Cetuximab as a Component of Multimodality Treatment of High-Risk Cutaneous Squamous Cell Carcinoma: A Retrospective Analysis From a Single Tertiary Academic Medical Center","volume":"45","author":"Trodello","year":"2019","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.ejca.2026.116764_bib122","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/DSS.0000000000001583","article-title":"Response of Cutaneous Squamous Cell Carcinoma to Treatment With Cetuximab","volume":"45","author":"Berliner","year":"2019","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.ejca.2026.116764_bib123","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/1754-9485.12842","article-title":"Cetuximab-radiotherapy combination in the management of locally advanced cutaneous squamous cell carcinoma","volume":"63","author":"Joseph","year":"2019","journal-title":"J Med Imaging Radiat Oncol"},{"key":"10.1016\/j.ejca.2026.116764_bib124","doi-asserted-by":"crossref","first-page":"7381","DOI":"10.1002\/cam4.3146","article-title":"Clinical outcomes among unresectable, locally advanced, and metastatic cutaneous squamous cell carcinoma patients treated with systemic therapy","volume":"9","author":"Cowey","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.ejca.2026.116764_bib125","doi-asserted-by":"crossref","first-page":"424","DOI":"10.3109\/09546634.2012.751481","article-title":"Efficacy of cetuximab in the treatment of squamous cell carcinoma","volume":"25","author":"Preneau","year":"2014","journal-title":"J Dermatol Treat"},{"issue":"8","key":"10.1016\/j.ejca.2026.116764_bib126","first-page":"932","article-title":"Cetuximab plus 5-fluorouracil in patients with advanced cutaneous squamous cell carcinoma: a retrospective cohort study","volume":"23","author":"Huynh","year":"2025","journal-title":"J der Dtsch Dermatol Ges = J Ger Soc Dermatol JDDG"},{"key":"10.1016\/j.ejca.2026.116764_bib127","doi-asserted-by":"crossref","DOI":"10.1111\/exd.14978","article-title":"Epidermal growth factor receptor inhibitors in advanced cutaneous squamous cell carcinoma: A systematic review and meta-analysis","volume":"33","author":"Pham","year":"2024","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.ejca.2026.116764_bib128","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15123180","article-title":"Cetuximab for Immunotherapy-Refractory\/Ineligible Cutaneous Squamous Cell Carcinoma","volume":"15","author":"Marin-Acevedo","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejca.2026.116764_bib129","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115379","article-title":"Immunotherapy followed by cetuximab in locally advanced\/metastatic cutaneous squamous cell carcinomas: the I-TACKLE trial","volume":"220","author":"Bossi","year":"2025","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2026.116764_bib130","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1093\/bjd\/ljaf303","article-title":"Avelumab plus cetuximab in patients with unresectable stage III or IV cutaneous squamous cell carcinoma: clinical activity and safety results from AliCe, a single-arm multicentre phase II DeCOG trial","volume":"193","author":"Becker","year":"2025","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2026.116764_bib131","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1200\/JCO-25-00759","article-title":"Phase II (Alliance A091802) Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma","volume":"43","author":"Zandberg","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116764_bib132","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1684\/ejd.2012.1845","article-title":"Complete response of metastatic cutaneous squamous cell carcinoma to cetuximab plus paclitaxel","volume":"22","author":"Mecca","year":"2012","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.ejca.2026.116764_bib133","doi-asserted-by":"crossref","first-page":"adv00637","DOI":"10.2340\/actadv.v101.751","article-title":"Real-world Treatment Patterns and Outcomes with Systemic Therapies in Unresectable Locally Advanced and Metastatic Cutaneous Squamous Cell Carcinoma in Germany","volume":"102","author":"Kramb","year":"2022","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.ejca.2026.116764_bib134","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1080\/0284186X.2018.1454602","article-title":"Updated standard operating procedures for electrochemotherapy of cutaneous tumours and skin metastases","volume":"57","author":"Gehl","year":"2018","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ejca.2026.116764_bib135","doi-asserted-by":"crossref","DOI":"10.1111\/dth.13547","article-title":"The use of cisplatin electrochemotherapy in nonmelanoma skin cancers: A single-center study","volume":"33","author":"De Giorgi","year":"2020","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.ejca.2026.116764_bib136","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ejca.2020.06.020","volume":"138","author":"Clover","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2026.116764_bib137","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.951662","article-title":"Electrochemotherapy for the treatment of cutaneous squamous cell carcinoma: The INSPECT experience (2008-2020)","volume":"12","author":"Bertino","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejca.2026.116764_bib138","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.ejso.2020.10.037","article-title":"Outcomes of older adults aged 90 and over with cutaneous malignancies after electrochemotherapy with bleomycin: A matched cohort analysis from the InspECT registry","volume":"47","author":"Sersa","year":"2021","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ejca.2026.116764_bib139","first-page":"470","article-title":"Prospective cohort study by InspECT on safety and efficacy of electrochemotherapy for cutaneous tumors and metastases depending on ulceration","volume":"20","author":"Claussen","year":"2022","journal-title":"J der Dtsch Dermatol Ges = J Ger Soc Dermatol JDDG"},{"key":"10.1016\/j.ejca.2026.116764_bib140","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMoa053422","article-title":"Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck","volume":"354","author":"Bonner","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.116764_bib141","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.ijrobp.2012.09.030","article-title":"Phase 1 study of erlotinib plus radiation therapy in patients with advanced cutaneous squamous cell carcinoma","volume":"85","author":"Heath","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ejca.2026.116764_bib142","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1200\/JCO.2006.05.9873","article-title":"Randomized trial of adjuvant 13-cis-retinoic acid and interferon alfa for patients with aggressive skin squamous cell carcinoma","volume":"25","author":"Brewster","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116764_bib143","article-title":"Role of Concurrent Systemic Therapy with Adjuvant Radiation Therapy for Locally Advanced Cutaneous Head and Neck Squamous Cell Carcinoma","volume":"9","author":"Goyal","year":"2017","journal-title":"Cureus"},{"key":"10.1016\/j.ejca.2026.116764_bib144","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.oraloncology.2018.01.015","article-title":"Combination of post-operative radiotherapy and cetuximab for high-risk cutaneous squamous cell cancer of the head and neck: A propensity score analysis","volume":"78","author":"Palmer","year":"2018","journal-title":"Oral Oncol"},{"key":"10.1016\/j.ejca.2026.116764_bib145","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1056\/NEJMoa2502449","article-title":"Adjuvant Cemiplimab or Placebo in High-Risk Cutaneous Squamous-Cell Carcinoma","volume":"393","author":"Rischin","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.116764_bib146","unstructured":"FDA approves cemiplimab-rwlc for adjuvant treatment of cutaneous squamous cell carcinoma. Available at: \u3008https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-cemiplimab-rwlc-adjuvant-treatment-cutaneous-squamous-cell-carcinoma\u3009, accessed on October 12, 2025."},{"key":"10.1016\/j.ejca.2026.116764_bib147","unstructured":"Libtayo\u00ae (cemiplimab) Approved in the European Union as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with High Risk of Recurrence after Surgery and Radiation. Available at: \u3008https:\/\/investor.regeneron.com\/news-releases\/news-release-details\/libtayor-cemiplimab-approved-european-union-first-and-only\u3009. Acessed on December 5, 2025."},{"key":"10.1016\/j.ejca.2026.116764_bib148","doi-asserted-by":"crossref","first-page":"6000","DOI":"10.1200\/JCO.2025.43.16_suppl.6000","article-title":"Phase III randomized trial (KEYNOTE 630) of adjuvant pembrolizumab in high risk re-sected locally advanced cutaneous squamous cell carcinoma","volume":"43","author":"Koyfman","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116764_bib149","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1001\/jamaoto.2024.0259","article-title":"Neoadjuvant-Intent Immunotherapy in Advanced, Resectable Cutaneous Squamous Cell Carcinoma","volume":"150","author":"Kim","year":"2024","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.ejca.2026.116764_bib150","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17101727","article-title":"Radiological, Pathological, and Surgical Outcomes with Neoadjuvant Cemiplimab for Stage II-IV Cutaneous Squamous Cell Carcinoma in the Deep Sequencing in Cutaneous Squamous Cell Carcinomas (DISCERN) Trial","volume":"17","author":"Lim","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejca.2026.116764_bib151","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1056\/NEJMoa2209813","article-title":"Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma","volume":"387","author":"Gross","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.116764_bib152","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/S1470-2045(23)00459-X","article-title":"Neoadjuvant cemiplimab and surgery for stage II-IV cutaneous squamous-cell carcinoma: follow-up and survival outcomes of a single-arm, multicentre, phase 2 study","volume":"24","author":"Gross","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2026.116764_bib153","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-025-03943-w","article-title":"Neoadjuvant ipilimumab and nivolumab in resectable cutaneous squamous cell carcinoma: a randomized phase 2 trial","author":"Breukers","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2026.116764_bib154","doi-asserted-by":"crossref","first-page":"4557","DOI":"10.1158\/1078-0432.CCR-21-0585","article-title":"Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck","volume":"27","author":"Ferrarotto","year":"2021","journal-title":"Clinical cancer research official journal American Association Cancer Research"},{"key":"10.1016\/j.ejca.2026.116764_bib155","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2025.07.029","article-title":"Satellitosis or in-transit metastasis in cutaneous squamous cell carcinoma: Risk factors and the prognostic significance","author":"Pahalyants","year":"2025","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.ejca.2026.116764_bib156","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1001\/jamadermatol.2022.0001","article-title":"Implications of Satellitosis or In-transit Metastasis in Cutaneous Squamous Cell Carcinoma: A Prognostic Omission in Cancer Staging Systems","volume":"158","author":"Smile","year":"2022","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ejca.2026.116764_bib157","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1097\/DSS.0000000000000864","article-title":"In-Transit Metastasis From Squamous Cell Carcinoma","volume":"42","author":"Ma","year":"2016","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.ejca.2026.116764_bib158","first-page":"651","article-title":"In-transit metastasis from primary cutaneous squamous cell carcinoma in organ transplant recipients and nonimmunosuppressed patients: clinical characteristics, management, and outcome in a series of 21 patients","volume":"30","author":"Carucci","year":"2004","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.ejca.2026.116764_bib159","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/jso.23481","article-title":"Electrochemotherapy for the management of cutaneous and subcutaneous metastasis: a series of 39 patients treated with palliative intent","volume":"109","author":"Solari","year":"2014","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.ejca.2026.116764_bib160","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/s41416-018-0149-z","article-title":"Isolated limb perfusion for unresectable extremity cutaneous squamous cell carcinoma; an effective limb saving strategy","volume":"119","author":"Huis In 't Veld","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2026.116764_bib161","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1080\/02656736.2016.1188999","article-title":"Isolated limb perfusion as a treatment option for rare types of tumours","volume":"32","author":"Belgrano","year":"2016","journal-title":"Int J Hyperth"},{"key":"10.1016\/j.ejca.2026.116764_bib162","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.jaad.2017.04.1108","article-title":"Efficacy of curettage alone for invasive cutaneous squamous cell carcinoma: A retrospective cohort study","volume":"77","author":"Yakish","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2026.116764_bib163","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jaad.2021.07.067","article-title":"Efficacy of nonexcisional treatment modalities for superficially invasive and in situ squamous cell carcinoma: A systematic review and meta-analysis","volume":"87","author":"Stewart","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2026.116764_bib164","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.jaad.2017.10.007","article-title":"Guidelines of care for the management of basal cell carcinoma","volume":"78","author":"Alam","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2026.116764_bib165","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1111\/jdv.16017","article-title":"European Dermatology Forum guidelines on topical photodynamic therapy 2019 Part 1: treatment delivery and established indications - actinic keratoses, Bowen's disease and basal cell carcinomas","volume":"33","author":"Morton","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ejca.2026.116764_bib166","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/jdv.16044","article-title":"European Dermatology Forum guidelines on topical photodynamic therapy 2019 Part 2: emerging indications - field cancerization, photorejuvenation and inflammatory\/infective dermatoses","volume":"34","author":"Morton","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ejca.2026.116764_bib167","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16010158","article-title":"Intralesional Treatments for Invasive Cutaneous Squamous Cell Carcinoma","volume":"16","author":"Baeza-Hernandez","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejca.2026.116764_bib168","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15233","article-title":"Effectiveness of neoadjuvant intralesional methotrexate in cutaneous squamous cell carcinoma: A prospective cohorts study","volume":"35","author":"Bergon-Sendin","year":"2022","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.ejca.2026.116764_bib169","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/j.jaad.2020.12.049","article-title":"Intralesional 5-fluorouracil for the treatment of squamous cell carcinomas","volume":"84","author":"Maxfield","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2026.116764_bib170","doi-asserted-by":"crossref","first-page":"CT004","DOI":"10.1158\/1538-7445.AM2024-CT004","article-title":"Abstract CT004: A single arm phase 2 study of TVEC in patients with invasive cutaneous SCC: A novel therapeutic approach for low risk tumors","volume":"84","author":"Curiel-Lewandrowski","year":"2024","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2026.116764_bib171","unstructured":"Results from the CERPASS Trial in CSCC. Replimune Press Release December 5, 2023. Accessed at \u3008https:\/\/ir.replimune.com\/news-releases\/news-release-details\/replimune-shares-initial-primary-analysis-results-cerpass\/\u3009 on Aug 29, 2025."},{"key":"10.1016\/j.ejca.2026.116764_bib172","doi-asserted-by":"crossref","first-page":"CT003","DOI":"10.1158\/1538-7445.AM2024-CT003","article-title":"Abstract CT003: Initial results from an open-label phase 1b\/2 study of RP1 oncolytic immunotherapy in solid organ transplant recipients with advanced cutaneous malignancies (ARTACUS)","volume":"84","author":"Migden","year":"2024","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2026.116764_bib173","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1093\/bjd\/ljaf027","article-title":"Skin cancer risk in more than 200 000 patients with haematological malignancies over 30 years: a nationwide population-based study in the Netherlands","volume":"192","author":"Eggermont","year":"2025","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2026.116764_bib174","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.det.2018.07.009","article-title":"Skin Cancer and Immunosuppression","volume":"37","author":"Collins","year":"2019","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.ejca.2026.116764_bib175","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-029265","article-title":"Behavioural and pharmaceutical interventions for the prevention of skin cancers in solid organ transplant recipients: a systematic review of randomised controlled trials","volume":"10","author":"James","year":"2020","journal-title":"BMJ Open"},{"key":"10.1016\/j.ejca.2026.116764_bib176","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1111\/bjd.15932","article-title":"Organ transplantation and cutaneous squamous cell carcinoma: progress, pitfalls and priorities in immunosuppression-associated keratinocyte carcinoma","volume":"177","author":"Harwood","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2026.116764_bib177","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1111\/bjd.15950","article-title":"Research gaps in the management and prevention of cutaneous squamous cell carcinoma in organ transplant recipients","volume":"177","author":"Blomberg","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2026.116764_bib178","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/s11864-012-0195-3","article-title":"Management of non-melanoma skin cancer in immunocompromised solid organ transplant recipients","volume":"13","author":"Bangash","year":"2012","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.ejca.2026.116764_bib179","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jaad.2025.02.076","article-title":"riSCC: A personalized risk model for the development of poor outcomes in cutaneous squamous cell carcinoma","volume":"93","author":"Jambusaria-Pahlajani","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2026.116764_bib180","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102150","article-title":"Personalised decision making to predict absolute metastatic risk in cutaneous squamous cell carcinoma: development and validation of a clinico-pathological model","volume":"63","author":"Rentroia-Pacheco","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.ejca.2026.116764_bib181","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1097\/DSS.0000000000003085","article-title":"Sentinel Lymph Node Biopsy in High-Risk Cutaneous Squamous Cell Carcinoma: Analysis of a Large Size Retrospective Series","volume":"47","author":"Tremblay-Abel","year":"2021","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.ejca.2026.116764_bib182","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.amjoto.2013.08.014","article-title":"Utility of positron emission tomography\/computed tomography for nodal staging of cutaneous squamous cell carcinoma in patients with chronic lymphocytic leukemia","volume":"35","author":"Tomaszewski","year":"2014","journal-title":"Am J Otolaryngol"},{"issue":"8","key":"10.1016\/j.ejca.2026.116764_bib183","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/jdv.15843","article-title":"Treatment approaches in immunosuppressed patients with advanced cutaneous squamous cell carcinoma","volume":"33","author":"Willenbrink","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ejca.2026.116764_bib184","first-page":"642","article-title":"Guidelines for the management of squamous cell carcinoma in organ transplant recipients","volume":"30","author":"Stasko","year":"2004","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.ejca.2026.116764_bib185","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/jdv.20103","article-title":"Mohs micrographic surgery in immunosuppressed vs immunocompetent patients: Results of a prospective nationwide cohort study (REGESMOHS, Spanish registry of Mohs surgery). J Eur","volume":"39","author":"Abril-Perez","year":"2025","journal-title":"Acad Dermatol Venereol"},{"key":"10.1016\/j.ejca.2026.116764_bib186","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/DSS.0000000000001645","article-title":"Association of Postoperative Antibiotics With Surgical Site Infection in Mohs Micrographic Surgery","volume":"45","author":"Levin","year":"2019","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.ejca.2026.116764_bib187","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1111\/ajt.14238","article-title":"Chemotherapy and Transplantation: The Role of Immunosuppression in Malignancy and a Review of Antineoplastic Agents in Solid Organ Transplant Recipients","volume":"17","author":"Krisl","year":"2017","journal-title":"Am J Transpl J Am Soc Transpl Am Soc Transpl Surg"},{"key":"10.1016\/j.ejca.2026.116764_bib188","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1001\/jamaoncol.2025.2374","article-title":"Outcomes of Solid Organ Transplant Recipients With Advanced Cancers Receiving Immune Checkpoint Inhibitors: A Systematic Review and Individual Participant Data Meta-Analysis","volume":"11","author":"Saleem","year":"2025","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2026.116764_bib189","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1200\/JCO.23.01497","article-title":"Nivolumab + Tacrolimus + Prednisone +\/- Ipilimumab for Kidney Transplant Recipients With Advanced Cutaneous Cancers","volume":"42","author":"Schenk","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116764_bib190","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/S1470-2045(22)00368-0","article-title":"Immune checkpoint inhibitors in kidney transplant recipients: a multicentre, single-arm, phase 1 study","volume":"23","author":"Carroll","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2026.116764_bib191","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1200\/JCO.23.01498","article-title":"Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma","volume":"42","author":"Hanna","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116764_bib192","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1097\/TP.0000000000004459","article-title":"Immune Checkpoint Inhibitors in Solid Organ Transplant Recipients With Advanced Skin Cancers-Emerging Strategies for Clinical Management","volume":"107","author":"Ferrandiz-Pulido","year":"2023","journal-title":"Transplantation"},{"key":"10.1016\/j.ejca.2026.116764_bib193","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/CCO.0000000000000505","article-title":"Immune checkpoint blockade for organ transplant patients with advanced cancer: how far can we go?","volume":"31","author":"De Bruyn","year":"2019","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.ejca.2026.116764_bib194","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s40425-019-0585-1","article-title":"Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature","volume":"7","author":"Abdel-Wahab","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2026.116764_bib195","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/j.jaad.2019.07.005","article-title":"Immune checkpoint inhibitor therapy in solid organ transplant recipients: A patient-centered systematic review","volume":"82","author":"Fisher","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2026.116764_bib196","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1111\/ajt.15811","article-title":"Efficacy and tolerance of immune checkpoint inhibitors in transplant patients with cancer: A systematic review","volume":"20","author":"d'Izarny-Gargas","year":"2020","journal-title":"Am J Transpl J Am Soc Transpl Am Soc Transpl Surg"},{"key":"10.1016\/j.ejca.2026.116764_bib197","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1634\/theoncologist.2019-0659","article-title":"The Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of Literature","volume":"25","author":"Kumar","year":"2020","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.ejca.2026.116764_bib198","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/jdv.17407","article-title":"Treatment of metastatic cutaneous squamous cell carcinoma in a solid organ transplant recipient with programmed death-1 checkpoint inhibitor therapy","volume":"36","author":"O'Connell","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ejca.2026.116764_bib199","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ejca.2018.09.017","article-title":"Anti-PD-1\/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B\/C infection","volume":"104","author":"Tio","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2026.116764_bib200","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000897","article-title":"Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patients","volume":"8","author":"Leiter","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2026.116764_bib201","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1007\/s10354-013-0213-5","article-title":"Cetuximab for treatment of advanced squamous cell carcinoma in solid organ transplant recipients","volume":"163","author":"Boyd","year":"2013","journal-title":"Wien Med Woche"},{"key":"10.1016\/j.ejca.2026.116764_bib202","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1200\/JCO.2013.49.2314","article-title":"Successful administration of ipilimumab to two kidney transplantation patients with metastatic melanoma","volume":"32","author":"Lipson","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116764_bib203","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ejca.2018.01.075","article-title":"Advanced cutaneous squamous cell carcinoma: A retrospective analysis of patient profiles and treatment patterns-Results of a non-interventional study of the DeCOG","volume":"96","author":"Hillen","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2026.116764_bib204","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.healun.2007.09.019","article-title":"Fatal diffuse alveolar damage in two lung transplant patients treated with cetuximab","volume":"26","author":"Leard","year":"2007","journal-title":"J Heart Lung Transpl"},{"key":"10.1016\/j.ejca.2026.116764_bib205","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/ajt.13593","volume":"16","author":"Zwald","year":"2016","journal-title":"Am J Transpl J Am Soc Transpl Am Soc Transpl Surg"},{"issue":"8","key":"10.1016\/j.ejca.2026.116764_bib206","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1111\/ajt.15856","article-title":"Kidney retransplantation after anti-programmed cell death-1 (PD-1)-related allograft rejection","volume":"20","author":"Lipson","year":"2020","journal-title":"Am J Transpl J Am Soc Transpl Am Soc Transpl Surg"},{"key":"10.1016\/j.ejca.2026.116764_bib207","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1600-6143.2012.04292.x","article-title":"A surveillance model for skin cancer in organ transplant recipients: a 22-year prospective study in an ethnically diverse population","volume":"13","author":"Harwood","year":"2013","journal-title":"Am J Transpl J Am Soc Transpl Am Soc Transpl Surg"},{"key":"10.1016\/j.ejca.2026.116764_bib208","doi-asserted-by":"crossref","first-page":"e133","DOI":"10.1097\/TP.0000000000001644","article-title":"Risk of Aggressive Skin Cancers After Kidney Retransplantation in Patients With Previous Posttransplant Cutaneous Squamous Cell Carcinomas: A Retrospective Study of 53 Cases","volume":"101","author":"Ducroux","year":"2017","journal-title":"Transplantation"},{"key":"10.1016\/j.ejca.2026.116764_bib209","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejca.2016.05.001","article-title":"European Research on Electrochemotherapy in Head and Neck Cancer (EURECA) project: Results of the treatment of skin cancer","volume":"63","author":"Bertino","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2026.116764_bib210","doi-asserted-by":"crossref","first-page":"165","DOI":"10.21037\/apm.2016.11.10","article-title":"Palliative radiotherapy for skin malignancies","volume":"6","author":"Vuong","year":"2017","journal-title":"Ann Palliat Med"},{"key":"10.1016\/j.ejca.2026.116764_bib211","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.21037\/apm-22-228","article-title":"Single-fraction high-dose palliative radiotherapy for facial cutaneous squamous cell carcinoma: a case report","volume":"11","author":"McLaughlin","year":"2022","journal-title":"Ann Palliat Med"},{"key":"10.1016\/j.ejca.2026.116764_bib212","unstructured":"World Health Organization (WHO). Palliative care. Available at: \u3008https:\/\/www.who.int\/health-topics\/palliative-care\u3009. Accessed on 10 October, 2022."},{"key":"10.1016\/j.ejca.2026.116764_bib213","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/SPC.0000000000000261","article-title":"Pain prevalence in cancer patients: status quo or opportunities for improvement?","volume":"11","author":"Haumann","year":"2017","journal-title":"Curr Opin Support Palliat Care"},{"key":"10.1016\/j.ejca.2026.116764_bib214","doi-asserted-by":"crossref","first-page":"515","DOI":"10.2147\/JPR.S97759","article-title":"Effectiveness of the World Health Organization cancer pain relief guidelines: an integrative review","volume":"9","author":"Carlson","year":"2016","journal-title":"J Pain Res"},{"key":"10.1016\/j.ejca.2026.116764_bib215","doi-asserted-by":"crossref","first-page":"146","DOI":"10.5114\/aoms.2018.72566","article-title":"Topical morphine for treatment of cancer-related painful mucosal and cutaneous lesions: a double-blind, placebo-controlled cross-over clinical trial","volume":"15","author":"Cialkowska-Rysz","year":"2019","journal-title":"Arch Med Sci"},{"key":"10.1016\/j.ejca.2026.116764_bib216","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1200\/JCO.18.00794","article-title":"Follow-Up of Patients With Complete Remission of Locally Advanced Basal Cell Carcinoma After Vismodegib Discontinuation: A Multicenter French Study of 116 Patients","volume":"37","author":"Herms","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116764_bib217","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1053\/ejso.1999.0931","article-title":"Educational tips in the treatment of malignant ulcerating tumours of the skin","volume":"26","author":"van Leeuwen","year":"2000","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ejca.2026.116764_bib218","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14051203","article-title":"Treatment Algorithm for Cancerous Wounds: A Systematic Review","volume":"14","author":"Furka","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejca.2026.116764_bib219","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/01.ASW.0000383206.32244.e2","article-title":"Local wound care for malignant and palliative wounds","volume":"23","author":"Woo","year":"2010","journal-title":"Adv Ski Wound Care"},{"key":"10.1016\/j.ejca.2026.116764_bib220","doi-asserted-by":"crossref","first-page":"3998","DOI":"10.1200\/JCO.22.01357","article-title":"Integrative Medicine for Pain Management in Oncology: Society for Integrative Oncology-ASCO Guideline","volume":"40","author":"Mao","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116764_bib221","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1186\/s12885-022-10213-2","article-title":"A nomogram combining clinical factors and biomarkers for predicting the recurrence of high-risk cutaneous squamous cell carcinoma","volume":"22","author":"Oh","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejca.2026.116764_bib222","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/hed.27233","article-title":"Impact of AJCC 8 pT staging in cutaneous head and neck squamous cell carcinoma in a nonselected real-world patient sample","volume":"45","author":"Girardi","year":"2023","journal-title":"Head Neck"},{"key":"10.1016\/j.ejca.2026.116764_bib223","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1001\/jamadermatol.2022.4590","article-title":"Follow-up of Patients With Keratinocyte Carcinoma: A Systematic Review of Clinical Practice Guidelines","volume":"159","author":"Mirali","year":"2023","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ejca.2026.116764_bib224","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/bjd.20974","article-title":"Topical treatment of actinic keratoses in organ transplant recipients: a feasibility study for SPOT (Squamous cell carcinoma Prevention in Organ transplant recipients using Topical treatments)","volume":"187","author":"Hasan","year":"2022","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2026.116764_bib225","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1001\/jamadermatol.2022.1034","article-title":"Risk of Invasive Cutaneous Squamous Cell Carcinoma After Different Treatments for Actinic Keratosis: A Secondary Analysis of a Randomized Clinical Trial","volume":"158","author":"Ahmady","year":"2022","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ejca.2026.116764_bib226","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1159\/000525974","article-title":"Influence of Frailty and Life Expectancy on Guideline Adherence and Outcomes in Cutaneous Squamous Cell Carcinoma of the Head and Neck: A Prospective Pilot Study","volume":"239","author":"Leus","year":"2023","journal-title":"Dermatology"},{"key":"10.1016\/j.ejca.2026.116764_bib227","doi-asserted-by":"crossref","DOI":"10.1111\/bjd.21250","article-title":"Risk factors for distant metastasis in cutaneous squamous cell carcinoma","author":"Stefanovic","year":"2022","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2026.116764_bib228","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.jaad.2024.06.072","article-title":"Most cutaneous squamous cell carcinoma recurrences occur in the first 3 years after diagnosis: A multicenter retrospective cohort study","volume":"91","author":"Granger","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2026.116764_bib229","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.amjoto.2017.01.035","article-title":"Rate of regional nodal metastases of cutaneous squamous cell carcinoma in the immunosuppressed patient","volume":"38","author":"McLaughlin","year":"2017","journal-title":"Am J Otolaryngol"},{"key":"10.1016\/j.ejca.2026.116764_bib230","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1001\/jamadermatol.2015.1702","article-title":"Outcomes of Patients With Multiple Cutaneous Squamous Cell Carcinomas: A 10-Year Single-Institution Cohort Study","volume":"151","author":"Levine","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ejca.2026.116764_bib231","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1001\/jamadermatol.2017.4506","article-title":"Cutaneous Squamous Cell Carcinomas in Solid Organ Transplant Recipients Compared With Immunocompetent Patients","volume":"154","author":"Cheng","year":"2018","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ejca.2026.116764_bib232","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1001\/jamadermatol.2018.4219","article-title":"Nationwide Incidence of Metastatic Cutaneous Squamous Cell Carcinoma in England","volume":"155","author":"Venables","year":"2019","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ejca.2026.116764_bib233","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1001\/jamadermatol.2015.4994","article-title":"Risk Factors for Cutaneous Squamous Cell Carcinoma Recurrence, Metastasis, and Disease-Specific Death: A Systematic Review and Meta-analysis","volume":"152","author":"Thompson","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ejca.2026.116764_bib234","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1001\/jamadermatol.2022.5508","article-title":"Association of Patient Risk Factors, Tumor Characteristics, and Treatment Modality With Poor Outcomes in Primary Cutaneous Squamous Cell Carcinoma: A Systematic Review and Meta-analysis","volume":"159","author":"Zakhem","year":"2023","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ejca.2026.116764_bib235","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1200\/JCO.2012.48.5326","article-title":"Evaluation of American Joint Committee on Cancer, International Union Against Cancer, and Brigham and Women's Hospital tumor staging for cutaneous squamous cell carcinoma","volume":"32","author":"Karia","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116764_bib236","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1001\/jamadermatol.2025.0128","article-title":"Risk Factor Number and Recurrence, Metastasis, and Disease-Related Death in Cutaneous Squamous Cell Carcinoma","volume":"161","author":"Ran","year":"2025","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ejca.2026.116764_bib237","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jaad.2016.08.051","article-title":"The positive impact of radiologic imaging on high-stage cutaneous squamous cell carcinoma management","volume":"76","author":"Ruiz","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2026.116764_bib238","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.jaad.2019.10.067","article-title":"Detection of subclinical disease with baseline and surveillance imaging in high-risk cutaneous squamous cell carcinomas","volume":"82","author":"Maher","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2026.116764_bib239","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.jaad.2018.09.006","article-title":"Nodal staging of high-risk cutaneous squamous cell carcinoma","volume":"81","author":"Fox","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2026.116764_bib240","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/bjd.16900","article-title":"Needs and preferences of patients regarding basal cell carcinoma and cutaneous squamous cell carcinoma care: a qualitative focus group study","volume":"180","author":"van Egmond","year":"2019","journal-title":"Br J Dermatol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926005459?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926005459?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T04:46:00Z","timestamp":1783485960000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926005459"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":240,"alternative-id":["S0959804926005459"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116764","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment - update 2026","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116764","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"116764"}}